Trastuzumab significantly increases the cure rate in patients with HER2 positive localized breast cancer, and has therefore become a standard adjuvant treatment for early stage breast cancer in many countries 5 <a href=https://ccialiss.icu>cheapest cialis online</a> 30 Quantifying bias in IPCW estimates can be difficult but will be limited as long as data are available about factors that affect patient decisions to cross over and are prognostic for future outcomes